Myeloma associated scleromyxedema with extensive involvement of small bowel

References

• Farhangi M, Merlini G. The clinical implications of monoclonal immunoglobulins. Sem Oncol 1986; 13: 366–79
   PubMed Web of Science ®Google Scholar
• Gabriel S E, Perry H O, Oleson G B, Bowles C A. Scleromyxedema: A scleroderma-like disorder with systemic manifestations. Medicine (Baltimore) 1988; 67: 58–65
   PubMed Web of Science ®Google Scholar
• Montgomery H, Underwood L J. Lichen myxedematosus. (Differentiation from cutaneous myxedemas or mucoid states). Invest Dermatol 1953; 20: 213–33
   Google Scholar
• Russell Jones R. Cutaneous manifestations of paraproteinaemia. Br J Dermatol 1981; 104: 209–20
   Google Scholar
• Truhan A P, Roenigk HH, Jnr. The cutaneous mucinoses. Am Acad Dermatol 1986; 14: 1–18
   Google Scholar
• Rongioletti F, Rebora A, Corvato F. Acral persistent papular mucinosis: a new entity. Arch Dermatol 1986; 122: 1237–9
   Google Scholar
• Kantor G R, Bergfeld W F, Katzin W E. Scleromyxedema associated with scleroderma renal disease and acute psychosis. J Am Acad Dermatol 1986; 14: 879–88
   Google Scholar
• Schnyder U W, Kaufmann J. Scleromyxoedema Arndt-Gottron Plasmozytom (IgG-kappa-type). Dermatologia 1979; 159: 407–12
   Google Scholar
• Krebs A, Muller A. Lichen myxoedematosus and multiple myeloma type IgG/kappa. Hautarzt 1980; 31: 644–53
   Google Scholar
• Bridgen W D, Calvert H T. Papular mucinosis (Scleromyxoedema of Arndt-Gottron) associated with paraprotein IgG kappa type. Proc Roy Soc Med 1974; 67: 12–13
   Google Scholar
• Bataille R, Rosenberg F, Sany J. Association d'un mucinose papuleuse et myeloma IgG Lambda. Sem Hop Paris 1978; 54: 865–9
   Google Scholar
• Muldrow M L, Bailin P D. Scleromyxedema associated with IgG lambda multiple myeloma. Cleve Clin Q 1983; 50: 189–95
   Google Scholar
• Proppe A, Becker V, Hardmeiter T. Skleromyxoderm Arndt-Gottron and plasmocytom Hautartz 1969; 20: 43–49
   Google Scholar
• James K, Fudenberg H, Epstein W L. Studies on a unique diagnostic serum globulin in papular mucinosis (lichen myxedematosis). Clin Exp Immunol 1967; 2: 153–66
   PubMedGoogle Scholar
• Harper R A, Rispler J. Lichen myxedematosus serum stimulates human fibroblast proliferation. Science 1978; 199: 545–7
   PubMed Web of Science ®Google Scholar
• Yaron M, Yaron I, Brenner S. Lichen myxedematosus (Scleromyxedema) serum stimulates hyaluronic acid and prostaglandin production by human fibroblasts. Rheumatol 1985; 12: 171–5
   Google Scholar
• Ferrarini M, Helfrich D J, Walker E R, Medsger T A, Whiteside T L. Scleromyxedema serum increases proliferation but not the glycoaminoglycan synthesis of dermal fibroblasts. J Rheumatol 1989; 16: 837–41
   Google Scholar
• Maeda H, Ishikawa H, Ohta S. Circumscribed myxedema of lichen myxedematosus as a sign of faulty formation of the protoglycan macromolecule. Br J Dermatol 1981; 105: 239–45
   Google Scholar
• Rudner N J, Mehregan A, Pinkus H. Scleromyxedema — a variant of lichen myxedematosus. Arch Dermatol 1966; 93: 6–12
   Google Scholar
• Helfrich D J, Walker E R, Martinez A J, Medsger T A, Jr. Scleromyxedema myopathy: Case report and review of the literature. Arthur Rheumat 1988; 31: 1437–41
   PubMedGoogle Scholar
• Fudman E J, Globus J, Ike R W. Scleromyxedema with systemic involvement mimics rheumatic disease. Arthr and Rheum 1986; 29: 913–7
   Google Scholar
• Johnson B L, Horowitz I R, Charles C R, Cooper D L. Dermatomyositis and lichen myxedematosus. Dermatologica 1973; 147: 109–22
   Google Scholar
• Alligood T R, Burnett J W, Raines B L. Scleromyxedema associated with esophageal aperistalsis and dermal eosinophilia. Cutis 1981; 18: 60–4
   Google Scholar
• Harris R B, Perry H O, Kyle R A, Winkleman R K. Treatment of scleromyxoedema with melphalan. Arch Dermatol 1979; 115: 295–9
   PubMedGoogle Scholar
• Donald G F, Hensley W J, McGovern V J. Myxoedematosus (papular mucinosis): a brief review of literature and report of a case which failed to respond to ACTH and cortisone. Aust J Dermatol 1953; 2: 28–36
   Google Scholar
• Farmer E R, Hambrick GW, Jnr., Schulman L E. Papular mucinosis. A clinicopathological study of four patients. Arch Dermatol 1982; 118: 9–13
   Google Scholar
• Perry H O, Montgomery H, Stickney J M. Further observations on lichen myxedematosus. Ann Intern Med 1960; 53: 955–69
   Google Scholar
• McCuiston C H, Schoch EP, Jnr. Autopsy findings in lichen myxedematosus. Arch Dermatol 1956; 74: 259–62
   Google Scholar
• Dalton J E, Booth B H, Gray H R, Evans P V. Lichen myxedematosus (papular mucinosis). Arch Dermatol 1961; 93: 230–42
   Google Scholar
• Hardie R A, Hunter J AA, Urbaniak S. Spontaneous resolution of lichen myxedematosus. Br J Dermatol 1979; 100: 727–30
   Google Scholar
• Farr P M, Ive F A. Puva treatment of scleromyxoedema. Br J Dermatol 1984; 110: 347–50
   PubMed Web of Science ®Google Scholar
• Penmetcha M, Highet A S, Hopkinson J M. Failure of puva in lichen myxoedematosus: acceleration of associated multiple keratoacanthomas with development of squamous carcinoma. Clin Exp Dermatol 1987; 12: 220–3
   PubMed Web of Science ®Google Scholar
• Macfarlane A W, Davenport A, Verbov J L, Goldsmith H J. Scleromyxoedema — a successful treatment with plasma exchange and immunosuppression. Br J Dermatol 1987; 117: 653–7
   Google Scholar
• Westheim A I, Lookingbill D F. Plasmopheresis in a patient with scleromyxedema. Arch Dermatol 1987; 123: 786–9
   PubMedGoogle Scholar
• Hill T G, Crawford J N, Rogers C C. Successful management of lichen myxedematosus. Arch Dermatol 1976; 112: 67–9
   PubMedGoogle Scholar